3:14 PM
 | 
Feb 14, 2018
 |  BC Extra  |  Preclinical News

TGFB inhibition could treat checkpoint inhibitor-resistant cancer

In two studies published in Nature, scientists uncovered the role of transforming growth factor (TGF) beta in the tumor microenvironment, and suggested that blocking TGF beta could help treat cancers resistant to checkpoint inhibitor therapies.

In the first paper, researchers from the Genentech Inc. unit of Roche (SIX:ROG; OTCQX:RHHBY) evaluated treatment response to PD-L1 inhibitor Tecentriq atezolizumab in patients from the Phase II IMvigor210 trial to treat metastatic urothelial cancer. Non-responders had increased CD8+ T cell expression and...

Read the full 373 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >